UK – Press Release: Beckley Psytech Bolsters Pipeline of Next-Generation Psychedelic Medicines With Research Collaboration and Strengthening of Relationship With Lophora ApS

UK – Press Release: Beckley Psytech Bolsters Pipeline of Next-Generation Psychedelic Medicines With Research Collaboration and Strengthening of Relationship With Lophora ApS
CANNANNEW REPORT

Beckley Psytech to collaborate with Lophora on researching New Clinical Entities (NCE’s) Broad collaboration with Lophora will further strengthen Beckley Psytech’s world class management and R&D team May 11, 2022 02:00 AM Eastern Daylight Time OXFORD, England–(BUSINESS WIRE)–Beckley Psytech Limited, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, and Lophora ApS, a drug discovery company working in the CNS arena, today announced the companies have entered into a research and development collaboration. Under the terms of the agreement Beckley Psytech will jointly fund continuing development of the Lophora pipeline and collaborate broadly on R&D. Founded in 2018 by University of Copenhagen’s Medicinal Chemistry Professor, Jesper Kristensen, Lophora is a highly regarded biotechnology company, based in Denmark, focused on the development of proprietary NCEs for treatment-resistant depression, and potential further indications including the treatment of anxiety, post-traumatic stress disorder, and substance abuse. Lophora has previously secured grant funding from the BioInovation Institute (Novo Nordisk Foundation) and continues to characterise its lead candidates, aiming to initiate clinical trials in 2023. Cosmo Feilding Mellen, CEO of Beckley Psytech, said: “The Lophora partnership represents a significant milestone for Beckley Psytech. It brings access to NCEs that we can take into Phase 1 studies in the near term, coupled with access to a drug discovery pipeline that we can shape together as our experience ever deepens in the psychedelic drug development space. Beckley Psytech has been working diligently to build a first-class drug development capability. This partnership is hugely exciting for us as we look to develop a portfolio of clinical assets that provide solutions to the devastating effect of psychiatric and neurological disorders.” Jesper Langgaard Kristensen, CSO of Lophora, commented: “Building on more than a decade’s worth of academic drug discovery, Lophora has unlocked the…

Excerpt only …
READ MORE BELOW
Source : UK – Press Release: Beckley Psytech Bolsters Pipeline of Next-Generation Psychedelic Medicines With Research Collaboration and Strengthening of Relationship With Lophora ApS

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.